Company intelligence / Profile preview
Mitotech
Luxembourg City/Luxembourg, Luxembourgmitotechpharma.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Mitotech develops mitochondria-targeted small molecule drugs, primarily based on its proprietary SkQ antioxidant technology. Its lead program, Visomitin™, has reached Phase 3 trials in the US for dry eye disease. The company also develops Plastomitin™, an oral formulation targeting systemic and neurodegenerative diseases. Early results suggest efficacy in reducing mitochondrial oxidative stress and inflammation across several age-related and rare disorders.
- Therapeutic areas
- OphthalmologyGastroenterologyNeurologyNephrology
- Modalities
- Small moleculesProteins
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Mitotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mitotech.